v3.6.0.2
Cash, cash equivalents and marketable securities
6 Months Ended
Dec. 30, 2016
Cash, cash equivalents and marketable securities
4. Cash, cash equivalents and marketable securities

The Company’s cash, cash equivalents, and marketable securities can be analyzed as follows:

 

            Fair Value  
(amount in thousands)    Carrying
Cost
     Unrealized
Loss
     Cash and
Cash
Equivalents
     Marketable
Securities
 

As of December 30, 2016

           

Cash

   $ 81,867       $ —         $ 81,867       $ —     

Cash equivalents

     3,752         —           3,752         —     

Corporate bonds and commercial papers

     114,692         (38      —           114,654   

U.S. agency and U.S. treasury securities

     54,211         (99      —           54,112   

Sovereign and municipal securities

     1,746         (4      —           1,742   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 256,268       $ (141    $ 85,619       $ 170,508   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

                   Fair Value  
(amount in thousands)    Carrying
Cost
     Unrealized
Gain
     Cash and
Cash
Equivalents
     Marketable
Securities
 

As of June 24, 2016

           

Cash

   $ 136,754       $ —         $ 136,754       $ —     

Cash equivalents

     6,050         —           6,050         —     

Corporate bonds and commercial papers

     112,128         394         —           112,522   

U.S. agency and U.S. treasury securities

     28,028         2         —           28,030   

Sovereign and municipal securities

     1,154         3         —           1,157   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 284,114       $ 399       $ 142,804       $ 141,709   
  

 

 

    

 

 

    

 

 

    

 

 

 

All highly liquid investments with original maturities of three months or less at the date of purchase are classified as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations at each balance sheet date. The Company may sell certain of its marketable securities prior to their stated maturities for strategic reasons including, but not limited to, anticipation of credit deterioration and duration management. The maturities of the Company’s marketable securities generally range from three months to three years. The Company’s investments in marketable securities consist of investments in U.S. Treasury and fixed income securities and have been classified and accounted for as available-for-sale.

The following table summarizes the cost and estimated fair value of marketable securities classified as available-for-sale securities based on stated effective maturities as of December 30, 2016:

 

(amount in thousands)    Carrying Cost      Fair Value  

Due within one year

   $ 22,773       $ 22,763   

Due between one to three years

     147,876         147,745   
  

 

 

    

 

 

 

Total

   $ 170,649       $ 170,508   
  

 

 

    

 

 

 

During the six months ended December 30, 2016, the Company recognized a realized loss of $0.02 million from sales and maturities of available-for-sale securities.

As of December 30, 2016, the Company considered the declines in market value of its marketable securities investment portfolio to be temporary in nature and did not consider any of its securities other-than-temporarily impaired. The Company typically invests in highly-rated securities, and its investment policy generally limits the amount of credit exposure to any one issuer. The policy requires investments generally to be investment grade, with the primary objective of minimizing the potential risk of principal loss. Fair values were determined for each individual security in the investment portfolio. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell, the investment before recovery of the investment’s cost basis. No impairment losses were recorded for the six months ended December 30, 2016.

As of December 30, 2016, cash, cash equivalents, and marketable securities included bank deposits of $40.0 million held in various financial institutions located in the United States in order to support the availability of the Facility Agreement (as defined in Note 11) and comply with covenants. As discussed in Note 11, under the terms and conditions of the Facility Agreement, the Company shall maintain cash, cash equivalents and/or marketable securities in an aggregate amount not less than $40.0 million in unencumbered deposits, and/or securities in accounts located in the United States at all times during the term of the Facility Agreement. The Company must comply with the covenant from and after the effective date of the Facility Agreement.